[2024年系统性氨基粉症的临床方面]
Sophie Georgin-Lavialle1, Gilles Grateau2
1Centre national de référence des maladies autoinflammatoires et de l'amylose inflammatoires (CEREMAIA) & ERN RITA & INSERM UMRS 1155, Paris, France; Service de médecine interne, hôpital Tenon,Sorbonne université, DMU3ID, Paris, France.
Annales de pathologie
|October 17, 2024
概括
系统性amyloidosis包括跨甲状腺素 (ATTR),免疫球蛋白 (AL) 和炎症性 (AA) 类型. 最近ATTR和AL治疗的进展改善了预后,而AA氨基粉症的原因正在多样化.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 神经学 神经学
- 类风湿病学 类风湿病学
- 遗传学 遗传学 是一个
背景情况:
- 系统性氨基粉症有三种主要类型:过素氨基粉症 (ATTR),免疫球蛋白氨基粉症 (AL) 和炎症性氨基粉症 (AA).
- ATTR氨基粉症包括野性类型,常见于心脏病,以及导致神经病变和心脏问题的遗传形式.
- 甲状腺 Amyloidosis是一种由有毒免疫球蛋白轻链影响器官,特别是心脏和脏的血液学疾病.
- 由于生物疗法,AA氨基粉症不太常见,并使慢性炎症状况复杂化,与肥胖相关的异常病例增加.
研究的目的:
- 为了提供对三种主要类型的全身性粉样化症的概述.
- 为了突出ATTR和AL氨基粉症的近期治疗进展.
- 讨论AA氨基粉症病因的不断变化的景观.
主要方法:
- 系统性氨基粉症类型的文献综述,重点关注跨素氨基粉症 (ATTR),免疫球蛋白氨基粉症 (AL) 和炎症性氨基粉症 (AA).
- 分析当前的治疗策略及其对患者预后的影响.
- 检查导致不同类型的amyloidosis亚型的病因因素.
主要成果:
- 用稳定剂和mRNA向药物治疗ATTR粉样性粉症已经取得了显著的治疗进展.
- 针对血细胞的有效治疗改善了AL氨基粉症的结果,尽管心脏参与仍然至关重要.
- 亚甲粉样粉症的发病率降低归因于对炎症疾病的生物疗法;然而,异常病例正在增加.
结论:
- 在ATTR和AL氨基粉症治疗的进步提供了改善的预后.
- 心脏和脏的参与仍然是AL氨基粉症的关键问题.
- 亚亚氨基粉症的病因正在扩大,需要进一步研究未知的原因和肥胖相关性.
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Chronic Kidney Disease II: Clinical Manifestations
2
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
2
Nephrotic Syndrome III : Nursing Management
2
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
2
Nephrotic Syndrome I : Introduction
2
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
2
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


